METHODS OF ADMINISTERING ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS
Self-administered pharmaceutical compositions of epinephrine and its prodrugs are described as having pharmacokinetic parameters that are comparable to those compositions administered by a health care professional and by intramuscular injection.
1 . A method of administering a pharmaceutical composition, comprising:
self-administering an oral film comprising:
a polymeric matrix;
a pharmaceutically active component including epinephrine or a prodrug of epinephrine in the polymeric matrix; and
an adrenergic receptor interacter;
positioning the film in an oral mucosa for a residence time; and
allowing the film to deliver the pharmaceutically active component.
2 . The method according to claim 1 , wherein self-administering the pharmaceutically active component in the oral film provides comparable pharmacokinetic parameters as delivery with a health care professional.
3 . The method according to claim 1 , wherein self-administering the pharmaceutically active component in the oral film provides comparable pharmacokinetic parameters as intramuscular injection.
4 . The method according to claim 2 , wherein the pharmacokinetic parameter is Cmax.
5 . The method according to claim 2 , wherein the pharmacokinetic parameter is Tmax.
6 . The method according to claim 4 , wherein the Cmax is greater than 34 pg/mL.
7 . The method according to claim 4 , wherein the Cmax is greater than 70 pg/mL.
8 . The method according to claim 4 , wherein the Cmax is greater than 150 pg/mL.
9 . The method according to claim 4 , wherein the Cmax is greater than 300 pg/mL.
10 . The method according to claim 4 , wherein the Cmax is in the range of 34-5000 pg/mL.
11 . The method according to claim 4 , wherein the Cmax is greater than 450 pg/mL.
12 . The method according to claim 4 , wherein the Cmax is less than 2850 pg/mL.
13 . The method according to claim 5 , wherein the Tmax is greater than 8 minutes.
14 . The method according to claim 5 , wherein the Tmax is greater than 15 minutes.
15 . The method according to claim 5 , wherein the Tmax is greater than 25 minutes.
16 . The method according to claim 5 , wherein the Tmax is greater than 40 minutes.
17 . The method according to claim 5 , wherein the Tmax is less than 30 minutes.
18 . The method according to claim 5 , wherein the Tmax is 8-50 minutes.
19 . The method according to claim 1 , wherein the composition further includes a mixture of adrenergic receptor interacters.
20 . The method according to claim 1 , wherein the adrenergic receptor interacter includes an aromatic compound.
21 . The method according to claim 1 , wherein the adrenergic receptor interacter includes a phenylpropanoid.
22 . The method according to claim 1 , wherein the adrenergic receptor interacter includes farnesol or Labrasol.
23 . The method according to claim 1 , wherein the adrenergic receptor interacter includes linoleic acid.
24 . The method according to claim 21 , wherein the phenylpropanoid is eugenol or eugenol acetate.
25 . The method according to claim 21 , wherein the phenylpropanoid is a cinnamic acid, cinnamic acid ester, cinnamic aldehyde or hydrocinnamic acid.
26 . The method according to claim 21 , wherein the phenylpropanoid is chavicol.
27 . The method according to claim 21 , wherein the phenylpropanoid is safrole.
28 . The method according to claim 1 , wherein the adrenergic receptor interacter is a phytoextract.
29 . The method according to claim 28 , wherein the phytoextract is synthetic or biosynthetic.
30 . The method according to claim 28 , wherein the phytoextract further includes an essential oil extract of a clove plant.